Goldman Sachs’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$47.2M Buy
730,140
+272,001
+59% +$19.2M 0.01% 1620
2025
Q4
$30.8M Sell
458,139
-226,384
-33% -$15.2M ﹤0.01% 1949
2025
Q3
$50.2M Sell
684,523
-683,179
-50% -$45.4M 0.01% 1414
2025
Q2
$71.1M Sell
1,367,702
-151,213
-10% -$8.6M 0.01% 1105
2025
Q1
$96.9M Sell
1,518,915
-331,718
-18% -$19.3M 0.02% 801
2024
Q4
$88.5M Sell
1,850,633
-124,001
-6% -$6.36M 0.01% 877
2024
Q3
$113M Buy
1,974,634
+1,195,743
+154% +$68.6M 0.02% 736
2024
Q2
$40.8M Sell
778,891
-42,495
-5% -$1.86M 0.01% 1316
2024
Q1
$33.4M Sell
821,386
-720,224
-47% -$27M 0.01% 1453
2023
Q4
$57M Sell
1,541,610
-190,795
-11% -$7.19M 0.01% 1098
2023
Q3
$66.2M Buy
1,732,405
+166,649
+11% +$6.83M 0.01% 953
2023
Q2
$56.5M Sell
1,565,756
-41,542
-3% -$1.42M 0.01% 1015
2023
Q1
$61.4M Sell
1,607,298
-385,908
-19% -$18.1M 0.01% 938
2022
Q4
$113M Buy
1,993,206
+9,265
+0.5% +$474K 0.03% 667
2022
Q3
$78.4M Buy
1,983,941
+322,702
+19% +$14.3M 0.02% 816
2022
Q2
$73.1M Sell
1,661,239
-301,458
-15% -$13M 0.02% 873
2022
Q1
$78.3M Sell
1,962,697
-802,550
-29% -$28.6M 0.02% 926
2021
Q4
$111M Buy
2,765,247
+497,705
+22% +$18.6M 0.02% 746
2021
Q3
$92.2M Buy
2,267,542
+320,657
+16% +$13.4M 0.02% 801
2021
Q2
$88.4M Sell
1,946,885
-677,824
-26% -$30M 0.02% 812
2021
Q1
$109M Sell
2,624,709
-12,104
-0.5% -$553K 0.03% 603
2020
Q4
$113M Buy
2,636,813
+91,332
+4% +$3.28M 0.03% 557
2020
Q3
$66.9M Buy
2,545,481
+1,059,566
+71% +$29.5M 0.02% 798
2020
Q2
$39.8M Buy
1,485,915
+496,546
+50% +$11.2M 0.01% 1144
2020
Q1
$17.8M Buy
989,369
+85,155
+9% +$1.62M 0.01% 1603
2019
Q4
$16M Sell
904,214
-699,487
-44% -$12.1M ﹤0.01% 2047
2019
Q3
$24.9M Buy
1,603,701
+201,257
+14% +$3.31M 0.01% 1614
2019
Q2
$24.1M Sell
1,402,444
-110,039
-7% -$1.78M 0.01% 1710
2019
Q1
$24.4M Sell
1,512,483
-393,325
-21% -$6.37M 0.01% 1711
2018
Q4
$27.9M Buy
1,905,808
+243,432
+15% +$3.88M 0.01% 1541
2018
Q3
$30.2M Buy
1,662,376
+184,636
+12% +$3.23M 0.01% 1606
2018
Q2
$24.9M Buy
1,477,740
+140,904
+11% +$2.66M 0.01% 1721
2018
Q1
$26.2M Buy
1,336,836
+462,703
+53% +$8.96M 0.01% 1631
2017
Q4
$17.7M Buy
874,133
+428,364
+96% +$7.88M ﹤0.01% 2024
2017
Q3
$7.74M Buy
445,769
+37,885
+9% +$513K ﹤0.01% 2780
2017
Q2
$5.23M Buy
407,884
+197,857
+94% +$2.64M ﹤0.01% 3019
2017
Q1
$2.72M Sell
210,027
-5,853
-3% -$74K ﹤0.01% 3459
2016
Q4
$2.13M Buy
215,880
+73,338
+51% +$803K ﹤0.01% 3799
2016
Q3
$1.72M Sell
142,542
-208,054
-59% -$2.13M ﹤0.01% 3957
2016
Q2
$3.03M Buy
350,596
+18,100
+5% +$179K ﹤0.01% 3257
2016
Q1
$3.15M Buy
332,496
+7,417
+2% +$69.8K ﹤0.01% 3095
2015
Q4
$5.63M Sell
325,079
-30,294
-9% -$483K ﹤0.01% 2715
2015
Q3
$4.77M Buy
355,373
+197,222
+125% +$3.96M ﹤0.01% 2930
2015
Q2
$3.57M Sell
158,151
-73,324
-32% -$1.29M ﹤0.01% 3262
2015
Q1
$3.31M Buy
231,475
+38,568
+20% +$556K ﹤0.01% 3300
2014
Q4
$1.86M Buy
192,907
+24,003
+14% +$213K ﹤0.01% 3912
2014
Q3
$1.54M Sell
168,904
-22,927
-12% -$218K ﹤0.01% 4179
2014
Q2
$1.9M Buy
191,831
+1,932
+1% +$16.4K ﹤0.01% 4036
2014
Q1
$2.41M Buy
189,899
+38,691
+26% +$574K ﹤0.01% 3797
2013
Q4
$2.27M Sell
151,208
-22,026
-13% -$283K ﹤0.01% 3937
2013
Q3
$1.91M Buy
173,234
+3,698
+2% +$30.8K ﹤0.01% 3956
2013
Q2
$1.35M Buy
+169,536
New +$1.08M ﹤0.01% 4125

Other funds holding HALO

Goldman Sachs's HALO Position: Q1 2026 in Review

Goldman Sachs increased its Halozyme (HALO) stake by 59% in Q1 2026, buying an estimated $19.2M and bringing the position to 730,140 shares worth $47.2M. The position accounts for 0.01% of the portfolio, ranked #1620.

Goldman Sachs first reported a position in HALO in Q2 2013 and has held it in 52 quarters since. The position peaked at $113M in Q4 2022. 634 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

  • Goldman Sachs held 730,140 shares of Halozyme worth $47.2M as of Q1 2026.
  • Goldman Sachs bought 272,001 Halozyme shares in Q1 2026, an estimated $19.2M.
  • Halozyme made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1620 holding.
  • Goldman Sachs first reported a position in Halozyme in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Halozyme position peaked at $113M in Q4 2022.
  • 634 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.